Iveta Kudaba

Medicine & Life Sciences

1. pembrolizumab 100%
2. Drug Therapy 76%
3. Trastuzumab 75%
4. Small Cell Lung Carcinoma 70%
5. Placebos 58%
6. Stomach Neoplasms 54%
7. Phase IV Clinical Trials 54%
8. atezolizumab 50%
9. pertuzumab 49%
10. Afatinib 48%
11. Vinorelbine 42%
12. Breast Neoplasms 40%
13. Safety 40%
14. Erlotinib Hydrochloride 40%
15. Phase III Clinical Trials 38%
16. Organized Financing 37%
17. Docetaxel 35%
18. Adenocarcinoma of Lung 33%
19. ErbB Receptors 32%
20. Non-Small Cell Lung Carcinoma 32%
21. Progression-Free Survival 32%
22. Albumins 27%
23. Etoposide 26%
24. Ligands 26%
25. Breast 24%
26. Randomized Controlled Trials 21%
27. Therapeutics 20%
28. Mutation 19%
29. Hematopoietic Stem Cells 18%
30. Neutropenia 17%
31. Expert Testimony 16%
32. Mortality 15%
33. Survival 14%
34. Neoplasms 14%
35. Esophagogastric Junction 10%
36. Population 9%
37. Febrile Neutropenia 9%
38. Erythrocyte Transfusion 9%
39. 4-nitrophenyl chloromethyl(phenyl)phosphinate 9%
40. Intention 9%
41. Medicine 8%
42. Clinical Trials 7%
43. Platinum 7%
44. Random Allocation 7%
45. Latvia 6%
46. Quality of Life 6%
47. Ilex 6%
48. Medical Writing 6%
49. Carboplatin 5%
50. Hospitalization 5%